Co­herus and Ab­b­Vie set­tle Hu­mi­ra biosim­i­lar dis­pute af­ter Mark Cuban's Cost Plus Drugs an­nounce­ment

Biosim­i­lars play­er Co­herus Bio­sciences has patched things up with Ab­b­Vie af­ter the phar­ma said Co­herus vi­o­lat­ed its non-ex­clu­sive li­cense to com­mer­cial­ize Yusim­ry, a biosim­i­lar of Hu­mi­ra, a rheuma­toid arthri­tis drug.

On June 6, Co­herus re­ceived a no­tice from Ab­b­Vie be­cause of Co­herus’ an­nounce­ment on June 1 of its pric­ing agree­ment with Mark Cuban Cost Plus Drug Com­pa­ny and its plans to of­fer Yusim­ry to Cost Plus Drugs cus­tomers be­gin­ning in Ju­ly, ac­cord­ing to SEC fil­ings.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER